Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Our recent research has unveiled the potential of locoregional immunotherapy. Cytokine-armored viral vectors, such as modified vaccinia virus Ankara vector encoding single-chain interleukin-12 (MVA.scIL-12), can target the omentum and elicit a robust tumor-specific immune response, all the while minimizing toxicity.

Original publication

DOI

10.1080/2162402x.2023.2285106

Type

Journal article

Journal

Oncoimmunology

Publication Date

01/2023

Volume

12

Addresses

Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.

Keywords

Omentum, Humans, Vaccinia virus, Peritoneal Neoplasms, Immunotherapy, Genetic Vectors